{
  "ticker": "SNT",
  "pdf_display_url": "https://www.asx.com.au/asx/v2/statistics/displayAnnouncement.do?display=pdf&idsId=02967021",
  "id": "02967021",
  "pages": 2,
  "price_sensitive": false,
  "date": "20250708",
  "time": "0826",
  "pdf_url": "https://announcements.asx.com.au/asxpdf/20250708/pdf/06lkx1q0vjxddl.pdf",
  "summary": "- **Material Information**:  \n  - **INN Granted**: WHO assigned the generic name \"amsulostat\" to SNT-5505, signaling global recognition and advancement in clinical development.  \n  - **Clinical Progress**: Phase 2 interim results show promising efficacy/safety for amsulostat in myelofibrosis (combined with ruxolitinib).  \n  - **Regulatory Milestones**: Follows recent FDA Fast Track Designation, reinforcing potential for accelerated development.  \n\n*Omitted*: Background on company, pipeline details beyond amsulostat, and forward-looking statements (non-material to immediate trading).",
  "usage": {
    "prompt_tokens": 1381,
    "completion_tokens": 127,
    "total_tokens": 1508,
    "prompt_tokens_details": null
  },
  "model": "deepseek/deepseek-chat-v3-0324:free",
  "processed_at": "2025-07-07T22:35:34.315515"
}